Lupus
Non-Interventional
Registry
How LRA Built the World’s Largest Lupus Registry—3,500 Patients in Under 6 Months
Lupus
Non-Interventional
Registry
How LRA Built the World’s Largest Lupus Registry—3,500 Patients in Under 6 Months
Lupus
Non-Interventional
Registry
How LRA Built the World’s Largest Lupus Registry—3,500 Patients in Under 6 Months
How LRA Built the World’s Largest Lupus Registry—3,500 Patients in Under 6 Months
Understanding and Treating Lupus
The Lupus Research Alliance (LRA) is the largest private funder of lupus research in the United States, with over $250 million in cumulative research investment. Despite significant efforts, few treatments exist for lupus due to the disease’s complexity and variability, making pathway discovery and drug development particularly challenging.
In 2022, LRA launched the Lupus Landmark Study, the largest observational study of its kind, aiming to accelerate the development of personalized lupus treatments. The study spans more than 20 investigational sites across the U.S. and Canada, targeting 3,500 participants. It collects comprehensive genomics, clinical, patient-reported data, and biosamples over a five-year period, seeking to transform lupus care through groundbreaking insights.
The Embleema Platform
Embleema’s clinical data platform was selected from a competitive pool of vendors, including leading CROs and registry providers, to run the study. What set Embleema apart was its ability to seamlessly integrate molecular, clinical, and patient-reported data, while also collecting real-world data (RWD) from over 60,000 care centers.
The platform’s no-code, configuration-based approach allowed for rapid deployment—launching the Lupus Landmark Study in less than six months. The company's user-friendly applications for patients and study coordinators, coupled with its comprehensive data quality and standardization tools, significantly reduced costs compared to traditional CRO solutions.
Study coordinator site app displays sample data for a Lupus Landmark Study participant.
Transforming Lupus Research
The Embleema platform enabled LRA to streamline data collection and management, ensuring high-quality, standardized data across all study sites. By leveraging real-world data and patient-reported outcomes, LRA is better positioned to identify disease patterns and inform personalized treatment strategies.
The success of the Lupus Landmark Study marks a major milestone in lupus research, paving the way for more precise and effective therapies in the future.
Curious how your organization can streamline data collection and optimize budgets with Embleema’s platform?
Understanding and Treating Lupus
The Lupus Research Alliance (LRA) is the largest private funder of lupus research in the United States, with over $250 million in cumulative research investment. Despite significant efforts, few treatments exist for lupus due to the disease’s complexity and variability, making pathway discovery and drug development particularly challenging.
In 2022, LRA launched the Lupus Landmark Study, the largest observational study of its kind, aiming to accelerate the development of personalized lupus treatments. The study spans more than 20 investigational sites across the U.S. and Canada, targeting 3,500 participants. It collects comprehensive genomics, clinical, patient-reported data, and biosamples over a five-year period, seeking to transform lupus care through groundbreaking insights.
The Embleema Platform
Embleema’s clinical data platform was selected from a competitive pool of vendors, including leading CROs and registry providers, to run the study. What set Embleema apart was its ability to seamlessly integrate molecular, clinical, and patient-reported data, while also collecting real-world data (RWD) from over 60,000 care centers.
The platform’s no-code, configuration-based approach allowed for rapid deployment—launching the Lupus Landmark Study in less than six months. The company's user-friendly applications for patients and study coordinators, coupled with its comprehensive data quality and standardization tools, significantly reduced costs compared to traditional CRO solutions.
Study coordinator site app displays sample data for a Lupus Landmark Study participant.
Transforming Lupus Research
The Embleema platform enabled LRA to streamline data collection and management, ensuring high-quality, standardized data across all study sites. By leveraging real-world data and patient-reported outcomes, LRA is better positioned to identify disease patterns and inform personalized treatment strategies.
The success of the Lupus Landmark Study marks a major milestone in lupus research, paving the way for more precise and effective therapies in the future.
Curious how your organization can streamline data collection and optimize budgets with Embleema’s platform?
Understanding and Treating Lupus
The Lupus Research Alliance (LRA) is the largest private funder of lupus research in the United States, with over $250 million in cumulative research investment. Despite significant efforts, few treatments exist for lupus due to the disease’s complexity and variability, making pathway discovery and drug development particularly challenging.
In 2022, LRA launched the Lupus Landmark Study, the largest observational study of its kind, aiming to accelerate the development of personalized lupus treatments. The study spans more than 20 investigational sites across the U.S. and Canada, targeting 3,500 participants. It collects comprehensive genomics, clinical, patient-reported data, and biosamples over a five-year period, seeking to transform lupus care through groundbreaking insights.
The Embleema Platform
Embleema’s clinical data platform was selected from a competitive pool of vendors, including leading CROs and registry providers, to run the study. What set Embleema apart was its ability to seamlessly integrate molecular, clinical, and patient-reported data, while also collecting real-world data (RWD) from over 60,000 care centers.
The platform’s no-code, configuration-based approach allowed for rapid deployment—launching the Lupus Landmark Study in less than six months. The company's user-friendly applications for patients and study coordinators, coupled with its comprehensive data quality and standardization tools, significantly reduced costs compared to traditional CRO solutions.
Study coordinator site app displays sample data for a Lupus Landmark Study participant.
Transforming Lupus Research
The Embleema platform enabled LRA to streamline data collection and management, ensuring high-quality, standardized data across all study sites. By leveraging real-world data and patient-reported outcomes, LRA is better positioned to identify disease patterns and inform personalized treatment strategies.
The success of the Lupus Landmark Study marks a major milestone in lupus research, paving the way for more precise and effective therapies in the future.
